Of note, genes involved in mTOR signaling, such as TSC1 and TSC2, were frequently mutated in HCC,[26, 27] and mTOR signaling was considered as one of the potential therapeutic targets for HCC‐LT with the absence of TLS.[28, 29] Previous studies have shown that mTOR inhibitors is effective in improving survival, as well as reducing recurrence for HCC patients following LT,[30, 31] suggesting that HCC‐LT with the absence of TLS might be a potential benefit group of mTOR inhibitors. The gene discussed is TSC2; the disease is hepatocellular carcinoma.